RxDoctor Payments Data

Carlos Garcia, MD

MOHS-Micrographic Surgery · Oklahoma City, OKNPI 1013985217

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 676 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.

$14,445in general payments, 2019–2025

Across 676 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Sanofi$2K
  • Johnson & Johnson$1K
  • Novartis$1K
  • UCB, Inc.$1K
  • plus $5K from 23 others

What the payments were for

  • Travel & lodging$110%
  • Food & beverage$14,23899%
  • Education$1961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$422,969
Medicare patients
659
Services billed
2,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab28$281,120
OdomzoSonidegib Phosphate28$199,254
Dupixent SyringeDupilumab14$54,272
Mupirocin324$3,146
Clobetasol Propionate40$1,678
Hydroxychloroquine Sulfate22$961
Minocycline Hcl19$862
Doxycycline Hyclate18$701
Fluocinolone Acetonide12$512
Triamcinolone Acetonide45$452
Cephalexin34$246
Ketoconazole18$194
Hydrocortisone15$125

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →